Shannon Trotter, DO, moderated a Dermatology Times Case-Based Roundtable event on how pharmacokinetics, adverse event timing, and trial response criteria should shape hedgehog pathway inhibitor selection in advanced BCC.
|Articles|May 25, 2023
POLL: What Type of Sunscreen Do You Recommend to Your Patients?
Author(s)Dermatology Times Staff
Click here to answer this week's poll.
Advertisement
What type of sunscreen do you recommend to your patients?
Melanoma May is not the only time to be concerned about sun protection and the risks of sun damage. As more summer months approach, it is crucial to urge patients to take sun protection seriously. The
If you're interested in sharing your sunscreen and sun protection recommendations, email us at
Advertisement
Related to this article
Phase 3 data show intismeran plus pembrolizumab reduced recurrence or death risk by 42% in patients with resected stage IIB-IV melanoma.
Cosibelimab-ipdl is now an NCCN Category 2A option for locally advanced CSCC in patients ineligible for curative surgery or radiation.
Two-year oral IL-23 data, GLP-1 biomarker findings, and a nonsurgical option for superficial basal cell carcinoma headline the sessions covered in Las Vegas.
Prospective data suggest DecisionDx-Melanoma may help refine SLNB decisions and identify recurrence risk beyond conventional staging.
Explore the top headlines of the month, including insights on the latest clinical trials, therapeutic updates, and more.
Dermatology Times is looking back on the top stories in dermatology from the month of October.
From “Botox in a bottle” to castor oil and face taping, Dermatology Times reviews the evidence behind 3 viral dermatology trends from October.
Advertisement
Advertisement